The Effects of L-arabinose on Intestinal Sucrase Activity in Man

Blood Glucose Clinical Trial

Official title:

The Effects of Increasing Doses of L-arabinose in a Sucrose Rich Meal on Intestinal Sucrase Activity in Man

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00302302
• Other study ID #: (KF) 01 270121
• Secondary ID: M181
• Status: Completed
• Phase: Phase 1
• First received: September 21, 2005
• Last updated: February 25, 2014
• Start date: September 2005
• Est. completion date: January 2006

Study information

• Verified date: February 2014
• Source: University of Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: The Danish National Committee on Biomedical Research Ethics
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effect of L-arabinose in a sugar-rich meal on intestinal sucrase activity in healthy volunteers by measuring postprandial blood glucose and insulin, and selected intestinal hormonal responses to increasing doses of L-arabinose.

Description:

Background:

The intake of common table sugar (sucrose) in the industrialised countries is relatively high. In Denmark the daily intake of sugar is in the range of 30-40 g/d exclusive the intake of sugar containing drinks. The health consequences of this relatively high sugar intake are heavily debated in the media. One of the arguments is that a high sugar intake may be one of the factors involved in the development of the metabolic syndrome, including overweight, increased blood glucose and insulin levels as well as impaired insulin action.

L-arabinose is widely distributed in plants and is a common component in plant cell walls in maize, wheat, rye, rice, plant gums etc. The isolated 5-carbon sugar has been shown to suppress the increase of blood glucose and plasma insulin after ingestion of sucrose in rats by inhibition of sucrase activity. In vitro studies on Caco-2 cells indicate that L-arabinose is a potent inhibitor on sucrase activity, possibly in a non-competitive way.

Potential nutritional advantages of consuming L-arabinose in combination with sucrose may therefore be a delayed digestion of sucrose and a lower absorption of glucose, resulting in both lower blood glucose and insulin levels. A delayed digestion of sucrose will reduce the energy utilisation with the potential of reducing weight gain in human subjects.

Methods:

This dose-response study with 14 healthy male volunteers has a randomised cross-over design based on four single "meals" separated by one week wash-out periods. Sugar rich drinks supplemented with different doses of L-arabinose will be tested with respect to postprandial blood glucose, insulin, triglyceride, glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1). Postprandial blood samples will be taken every 15 to 30 min for 180 min. Appetite sensations will be measured every 30 min during the experiment. After 180 minutes a lunch will be served and energy intake (EI) will be registered.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: January 2006
• Est. primary completion date: November 2005
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• healthy males

• BMI between 18.4-25 kg/m2

• age between 18 and 30

Exclusion Criteria:

• donation of blood 3 months before or during the study

• gastrointestinal disorders, diabetes, hypertension, hyperlipidemia, chronic infectious disease (HIV or hepatitis)

• smoking

• consumption of more than 21 alcoholic drinks/week

• elite athletes

• on medication

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Blood Glucose

Intervention

Drug:
• L-arabinose

Locations

Country	Name	City	State
Denmark	Institute of Human Nutrition, The Royal Veterinary and Agricultural University	Frederiksberg

Sponsors (2)

Lead Sponsor	Collaborator
University of Copenhagen	Danisco

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma glucose, insulin, triglycerides, GIP and GLP-1	Blood samples 2 hours after a test meal	2 hours	No
Secondary	Appetite measurements and energy intake	measured after a test meal	10 hours	No